Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
probiotic-Mayo Clinic
- Development stage
- Unknown
- Lead developer
- Mayo Clinic
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Probiotic-Mayo Clinic refers to a probiotic intervention being investigated by the Mayo Clinic in a clinical trial (NCT04699721) for its potential to modulate the gut microbiome and enhance the immune response in patients with operable stage I-III breast or lung cancer. The study, titled "Engineering Gut Microbiome to Target Cancer-Immune Microenvironment in Breast and Lung Cancer," evaluates whether oral administration of probiotics can increase the diversity of intestinal bacteria and alter the immune system's ability to recognize and react to cancer cells prior to surgery. This pilot study aims to provide insights into the relationship between the gut microbiome and the cancer-immune microenvironment, potentially identifying how microbial engineering can be used to improve outcomes in surgical oncology.
- Other names
- Probiotic
Beyond the preview
Go deeper on probiotic-Mayo Clinic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on probiotic-Mayo Clinic.